Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paolo Cappella

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Molecular Cancer Therapeutics|December 20, 2007
PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancerPatrizia Carpinelli, Roberta Ceruti, Maria Laura Giorgini, et al.
Journal of Medicinal Chemistry|April 15, 2005
Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibitionDaniele Fancelli, Daniela Berta, Simona Bindi, et al.
Molecular Cancer Therapeutics|February 10, 2012
NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignanciesBarbara Valsasina, Italo Beria, Cristina Alli, et al.
Journal of Medicinal Chemistry|November 28, 2006
1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profileDaniele Fancelli, Jürgen Moll, Mario Varasi, et al.
Journal of Medicinal Chemistry|April 20, 2010
Identification of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as a new class of orally and selective Polo-like kinase 1 inhibitorsItalo Beria, Dario Ballinari, Jay Aaron Bertrand, et al.
Journal of Experimental & Clinical Cancer Research : CR|May 10, 2017
FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patientsRenata A Tassi, Paola Todeschini, Eric R Siegel, et al.
Bioorganic & Medicinal Chemistry|September 7, 2010
Thieno[3,2-c]pyrazoles: a novel class of Aurora inhibitors with favorable antitumor activitySimona Bindi, Daniele Fancelli, Cristina Alli, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Molecular Cancer Therapeutics|December 20, 2007
PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancerPatrizia Carpinelli, Roberta Ceruti, Maria Laura Giorgini, et al.
Journal of Medicinal Chemistry|April 15, 2005
Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibitionDaniele Fancelli, Daniela Berta, Simona Bindi, et al.
Molecular Cancer Therapeutics|February 10, 2012
NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignanciesBarbara Valsasina, Italo Beria, Cristina Alli, et al.
Journal of Medicinal Chemistry|November 28, 2006
1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profileDaniele Fancelli, Jürgen Moll, Mario Varasi, et al.
Journal of Medicinal Chemistry|April 20, 2010
Identification of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as a new class of orally and selective Polo-like kinase 1 inhibitorsItalo Beria, Dario Ballinari, Jay Aaron Bertrand, et al.
Journal of Experimental & Clinical Cancer Research : CR|May 10, 2017
FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patientsRenata A Tassi, Paola Todeschini, Eric R Siegel, et al.
Bioorganic & Medicinal Chemistry|September 7, 2010
Thieno[3,2-c]pyrazoles: a novel class of Aurora inhibitors with favorable antitumor activitySimona Bindi, Daniele Fancelli, Cristina Alli, et al.
Pageof 3